283 related articles for article (PubMed ID: 32399998)
21. Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population.
Liu D; Liu X
Medicine (Baltimore); 2018 Dec; 97(49):e13358. PubMed ID: 30544402
[TBL] [Abstract][Full Text] [Related]
22. A Comprehensive Analysis of Influence ERCC Polymorphisms Confer on the Development of Brain Tumors.
Geng P; Ou J; Li J; Liao Y; Wang N; Xie G; Sa R; Liu C; Xiang L; Liang H
Mol Neurobiol; 2016 May; 53(4):2705-14. PubMed ID: 26264164
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
24. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
25. ERCC polymorphisms and prognosis of patients with osteosarcoma.
Li J; Liu S; Wang W; Zhang K; Liu Z; Zhang C; Chen S; Wu S
Tumour Biol; 2014 Oct; 35(10):10129-36. PubMed ID: 25023406
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
27. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
28. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
[TBL] [Abstract][Full Text] [Related]
29. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
[TBL] [Abstract][Full Text] [Related]
30. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838
[TBL] [Abstract][Full Text] [Related]
31. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
[TBL] [Abstract][Full Text] [Related]
33. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract][Full Text] [Related]
34. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
Zhao F; Shang Y; Zeng C; Gao D; Li K
Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer: An observational study from a tertiary cancer center in South India.
Kalidindi AV; Dubashi B; Jayanthi M; Shewade DG
Indian J Cancer; 2022; 59(1):73-79. PubMed ID: 33402602
[TBL] [Abstract][Full Text] [Related]
36. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
[TBL] [Abstract][Full Text] [Related]
37. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract][Full Text] [Related]
38. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
39. Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.
Qixing M; Gaochao D; Wenjie X; Rong Y; Feng J; Lin X; Mantang Q; Qiang C
Medicine (Baltimore); 2015 Sep; 94(39):e1593. PubMed ID: 26426637
[TBL] [Abstract][Full Text] [Related]
40. Study of association between pre-senile cataracts and rs11615 of ERCC1, rs13181 of ERCC2, and rs25487 of XRCC1 polymorphisms in a Spanish population.
López-Valverde G; Garcia-Martin E; Fernández-Mateos J; Cruz-González F; Larrosa-Povés JM; Polo-Llorens V; Pablo-Júlvez LE; González-Sarmiento R
Ophthalmic Genet; 2017; 38(4):314-319. PubMed ID: 27668351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
